Theravance Biopharma Inc Market Cap ($854.78 Million)
Market Cap & Net Worth: Theravance Biopharma Inc (TBPH)
Theravance Biopharma Inc market cap. Theravance Biopharma Inc (NASDAQ:TBPH) has a market capitalization of $854.78 Million ($854.78 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9203 globally and #2616 in its home market, demonstrating a -0.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theravance Biopharma Inc's stock price $17.03 by its total outstanding shares 51492924 (51.49 Million).
Theravance Biopharma Inc Market Cap History (2015–2026)
Theravance Biopharma Inc market cap history from 2015 to 2026. Data shows growth from $843.97 Million to $876.92 Million (1.86% CAGR). Check current stock price of Theravance Biopharma Inc for real-time trading data and today's change.
Index Memberships
Theravance Biopharma Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.03% | #265 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #988 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.05% | #155 of 263 |
Weight: Theravance Biopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Theravance Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theravance Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Theravance Biopharma Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
8.97x
Theravance Biopharma Inc's market cap is 8.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.10x
Theravance Biopharma Inc's market cap is 9.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.64 Billion | $48.65 Million | -$190.67 Million | 33.74x | N/A |
| 2017 | $1.44 Billion | $15.39 Million | -$285.40 Million | 93.34x | N/A |
| 2018 | $1.32 Billion | $60.37 Million | -$215.52 Million | 21.83x | N/A |
| 2019 | $1.33 Billion | $73.41 Million | -$236.46 Million | 18.16x | N/A |
| 2020 | $915.03 Million | $71.86 Million | -$278.02 Million | 12.73x | N/A |
| 2021 | $569.00 Million | $55.31 Million | -$199.43 Million | 10.29x | N/A |
| 2022 | $577.75 Million | $51.35 Million | $872.13 Million | 11.25x | 0.66x |
| 2023 | $578.78 Million | $57.42 Million | -$55.19 Million | 10.08x | N/A |
| 2024 | $484.55 Million | $64.38 Million | -$56.42 Million | 7.53x | N/A |
| 2025 | $963.43 Million | $107.46 Million | $105.89 Million | 8.97x | 9.10x |
Competitor Companies of TBPH by Market Capitalization
Companies near Theravance Biopharma Inc in the global market cap rankings as of October 31, 2026. See TBPH equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to Theravance Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Theravance Biopharma Inc (2015–2026)
Market capitalization of Theravance Biopharma Inc from 2015 to today. Between 2015 and today, Theravance Biopharma Inc's market cap moved from $843.97 Million to $ 876.92 Million, with a yearly change of 1.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $876.92 Million | -8.98% |
| 2025 | $963.43 Million | +98.83% |
| 2024 | $484.55 Million | -16.28% |
| 2023 | $578.78 Million | +0.18% |
| 2022 | $577.75 Million | +1.54% |
| 2021 | $569.00 Million | -37.82% |
| 2020 | $915.03 Million | -31.36% |
| 2019 | $1.33 Billion | +1.17% |
| 2018 | $1.32 Billion | -8.25% |
| 2017 | $1.44 Billion | -12.52% |
| 2016 | $1.64 Billion | +94.51% |
| 2015 | $843.97 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Theravance Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $854.78 Million USD |
| MoneyControl | $854.78 Million USD |
| MarketWatch | $854.78 Million USD |
| marketcap.company | $854.78 Million USD |
| Reuters | $854.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic n… Read more